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THE LEFT VENTRICLE: TO
RECONSTRUCT OR NOT—
LESSONS FROM THE STICH
TRIAL
To the Editor:
Recently at the 89th Annual Meeting
of The American Association for Tho-
racic Surgery in Boston, May 9–13,
2009, there was a very clarifying
debate on the STICH trial1 (Surgical
Treatment for Ischemic Heart Failure)
between Dr Robert H. Jones (pro) and
Dr Gerald D. Buckberg (con), moder-
ated by Dr Andrew S. Wechsler, which
sparked the following thoughts.
Clearly, surgeons involved in the
STICH trial had a difficult job: they
were instructed to include patients in
the trial if they honestly believed
they could undergo coronary artery
bypass grafting (CABG) either alone
or in combination with surgical ven-
tricular reconstruction (SVR) with
safety. It would seem likely that, ethi-
cally, patients with either global
hypokinesis (no clear-cut aneurysm)
or those with large aneurysms would
be hard to include in this trial. Also, re-
sults of the two patient groups (CABG
alone vs CABGþSVR) are uncannily
similar: identical improvements in
congestive heart failure and angina
class for both groups (1.7 and 1.0, re-
spectively), increase in distance on
the 6-minute walk test (48 vs 52 m),
death or hospital readmission for car-
diac cause (59% vs 58%), death
from any cause (28% vs 28%), hospi-
talization for cardiac cause (42% vs
41%), and operative mortality as-
treated (5% vs 6%) or as intention-
to-treat (5% vs 5%). These results
are practically identical as if coming
from a single patient population
divided in half..because they are.
They were selected by ethical sur-
geons aware of the extensive current
literature by many expert surgeon-
scientists working on hibernating
myocardium (no aneurysm, poor ven-
tricles) and overgrown ventricles
resulting from infarction (aneurysm
causing poor function). Perhaps
during the conception of STICH such
knowledge was not available, but per-
haps the performance of SVR (or not)
has reached the level of the ‘‘random-
ized controlled study of the para-
chute.’’ The real message of the
STICH trial is this: if one is pondering
treatment of patients with poor
ventricular function and mild aneurys-
mal dilatation, do not perform the
SVR surgery, because if you do not
send the patient to heaven, you will
only prolong his or her and your own
suffering (increased crossclamp, oper-
ative, and intensive care unit times and
total length of stay) with no clinical
benefit in ensuing years. The STICH
investigators and surgeons are to be
congratulated for their ethical dealing
with this controversial topic. How-
ever, the message that CABG surgery
alone is enough for patients with cor-
onary artery disease and left ven-
tricular aneurysms should not be
interpreted from the STICH trial, as
many patients with disabling left ven-
tricular aneurysms would be at risk for
the wrong treatment.
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LETTERS TO THE EDITORCLARIFICATION OF
STATEMENTS MADE
REGARDING INVESTIGATION
INTO AMPLATZER DEVICE
COMPLICATION INCIDENCE
AND COMPARISON WITH THE
SOCIETY OF THORACIC
SURGERY DATABASE
To the Editor:
As the corresponding first author and
presenter of the article regarding the
Amplatzer device (AGA Medical
Corporation, Plymouth, Minn) compli-
cations and comparison with the Soci-
ety of Thoracic Surgery database,1
I must clarify some statements made re-
garding the work of previous authors on
the complications of the Amplatzer de-
vice.2 In formulating a calculation that
was used to estimate complication fre-
quency, we based our mathematics on
estimates that were previously used by
Amin and colleagues.2 Our point in not-
ing that there was financial disclosure in
the previous work was not to suggest
that the data were not accurate. In fact,
we were counting on the accuracy of
these data because we also used the
data for our calculation. Rather than
questioning the work of these authors,
we were in fact relying on the integrity
of their estimates to make our own cal-
culations. The authors most closely as-
sociated with this device serve as the
best possible source of such informa-
tion, and highlighting this relationship
was only intended to add validity to
our own calculation.
There was absolutely no intended
implication of foul play or acting in
conflict of interest in the case of these
authors and indeed no such accusation
was directly made. That some compli-
cations go unreported to the MAUDE
database is most probably true but
this has nothing to do with the work
of Amin and colleagues,2 and these
must be kept seperate in the readers’
minds to understand the spirit of this
work. The previous publications on
the complications with Amplatzer de-
vices were as accurate as any, and
our addition to the literature presents
the most up to date. That the frequency009
PULMONARYARTERIAL
HYPERTENSION AND
CONGENITAL HEART
DISEASE: TARGETED
THERAPIES AND
OPERABILITY
To the Editor:
We read with great interest the case
report of Hoetzenecker and colleagues1
of a patient with severe pulmonary arte-
rial hypertension associated with an
atrial septal defect and the beneficial
effect of bosentan, which allowed for
closure of the defect. This is a very inter-
esting topic that raises a lot of cont-
roversies in the field of pulmonary
arterial hypertension associated with
congenital heart disease.2
I would like to comment on the he-
modynamic data presented in Table 1.
Total pulmonary resistance at baseline
is calculated at 460 dynes $ s1 $ cm5,
but pulmonary vascular resistance,
taking the mean left atrial pressure in
the calculation, which is commonly
done in congenital heart disease,
would give a value of 311 dynes $
s1 $ cm5 or 3.9 Wood units, which
lowing for the use of calcium channel
blockers, but this may not be applied
for the evaluation of operability in pa-
tients with congenital heart disease.
Why did the authors think that this par-
ticular patient required bosentan treat-
ment based on these measurements? If
we look at the data after treatment and
just before repair, the hemodynamic
does not look much better than with
nitric oxide, as the pulmonary vascular
resistance is 2.6 Wood units or 205
dynes $ s1 $ cm5 and Qp/Qs is 2.24.
Why was the patient considered oper-
able with these values but not before?
If this is based only on mPAP, I would
suggest the authors should discuss the
fact that mLAP also had a significant
decrease.
Finally, if we analyze the measure-
ment 8 months after repair, the pulmo-
nary vascular resistance is 4.2 and the
mean pulmonary arterial pressure is
35 mm Hg—still not normal. We
clearly hope that these values will re-
main at these levels and not rise again
in the coming month, as the outcome,
at least in pediatric patients with recur-
Letters to the Editorof said complications is increasing
may be true, but this again had nothing
to do with the integrity of previous es-
timates made in a good faith effort to
study results. I hope this clarifies any
question in the readers’ minds as to
the intention of my statements regard-
ing this issue.
Daniel J. DiBardino, MD
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The obituary of Dr DeBakey was
very interesting.1 One of Dr DeBakey’s
pioneering efforts does need special
emphasis. By using autologous saphe-
nous vein(s), on November 23, 1964,2
DeBakey performed the first human
coronary artery bypass graft surgery
to the left anterior descending coronary
artery in an asymptomatic patient after
myocardial infarction.
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is very close to a value of 3 Wood units
considered as totally safe for surgical
repair. If we calculate the ratio of pul-
monary to systemic blood flow (Qp/
Qs), we have a value of 2.7, which is
also considered a value that allows
for repair.
Moreover, when we look at the data
during the nitric oxide testing, these
values reach a pulmonary vascular resis-
tance of 1.78 Wood units or 142 dynes $
s1 $ cm5, the Qp/Qs is 3.25, and the
pulmonary arterial saturation reaches
84.5%. All these values are consistent
with a reactive pulmonary vascular
bed and are values that will clearly al-
low closure of the shunt for a congenital
cardiologist.3,4 It would be of interest
also to report the ratio of pulmonary
over systemic vascular resistance, as
a ratio<0.33 indicates good prognosis
after closure of the shunt.4
Maybe the authors used the defini-
tion of reactivity used for other forms
of pulmonary arterial hypertension, al-
rent pulmonary hypertension after re-
pair, is dismal, as shown recently by
Haworth and colleagues.5
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